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Abstract: Feline immunodeficiency virus (FIV) is a lentivirus of domestic cats worldwide. Diagnosis
usually relies on antibody screening by point-of-care tests (POCT), e.g., by enzyme-linked
immunosorbent assays (ELISA), and confirmation using Western blot (WB). We increasingly
observed ELISA-negative, WB-positive samples and aimed to substantiate these observations
using 1194 serum/plasma samples collected from 1998 to 2019 primarily from FIV-suspect cats.
While 441 samples tested positive and 375 tested negative by ELISA and WB, 81 samples had
discordant results: 70 were false ELISA-negative (WB-positive) and 11 were false ELISA-positive
(WB-negative); 297 ambiguous results were not analyzed further. The diagnostic sensitivity and
specificity of the ELISA (82% and 91%, respectively) were lower than those reported in 1995 (98% and
97%, respectively). The diagnostic efficiency was reduced from 97% to 86%. False ELISA-negative
samples originated mainly (54%) from Switzerland (1995: 0%). Sixty-four false ELISA-negative
samples were available for POCT (SNAPTM/WITNESSR): five were POCT-positive. FIV RT-PCR
was positive for two of these samples and was weakly positive for two ELISA- and POCT-negative
samples. Low viral loads prohibited sequencing. Our results suggest that FIV diagnosis has become
more challenging, probably due to increasing travel by cats and the introduction of new FIV isolates
not recognized by screening assays.
Keywords: Feline immunodeficiency virus; retrovirus; lentivirus; domestic cat; serology; point-of-care
test; Western blot; gold standard; veterinary sciences
1. Introduction
Feline immunodeficiency virus (FIV) is a lentivirus with a worldwide distribution [1–3]. Infection
with this retrovirus can lead to immunodeficiency in domestic cats [1,2,4] while the pathogenic
potential in wild felids is less well known [3,5–9]. Due to a lack of proofreading capacity of the reverse
transcriptase, there is a high error rate during replication and low replicative fidelity [10–13]. Currently,
five major clades or subtypes of FIV (A–E) have been described based on phylogenetic analyses of the
variable regions 3–5 of the FIV env gene as well as a portion of the gag gene [14–18]. While there is
some genetic intraclade diversity, the genetic distance between different FIV clades was found to be
more than 17% [14,15,17]. Recently, strains were tentatively assigned to new clades in Brazil, Turkey,
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the USA, Portugal, and New Zealand, of which the two latter clusters exhibit the new subtypes F and
U-NZenv [19–24].
FIV clade A strains are found worldwide [16,25–28]; the other clades show varying geographic
prevalence, and the separate evolution of these clades in geographical distinct areas [14,29] and
introduction into other areas has been proposed [15,26,30–33]. The most prevalent FIV clades found
in Europe are A and B, with clade A being predominant in Northern Europe (Germany, Benelux,
and the UK) [16,32,34–36] and clade B occurring more frequently in Southern Europe (Portugal, Italy,
Austria, Croatia, and Turkey) [16,20,24,29,34,37]. In North America, FIV clades A, B, and C have been
described [15,16,31,33]. In South America, clades A, B, and E have been reported, with clades B and
E being predominant and clade E only being described in this geographic area so far [18,28,38–41].
Limited information on the FIV strains and clades is available for Asia. Clade C seems to be the most
common in Taiwan and Vietnam [30,42,43]. Subtype A has been described in China [44], and subtypes
A, B, C, and D have been reported in Japan. B and D were the most prevalent subtypes, and clade D
was found only in Japan and Vietnam [26,30]. Clades A and B are distributed in Australia [45,46], while
A, C, and U-NZenv are found in New Zealand [27]. Interestingly, a cat can be infected concurrently
with several FIV strains [47–49]. Overall, the geographically restricted evolution of some subtypes,
such as D, E, and F, and the increasing import of domestic cats, some of them possibly coinfected with
FIV strains of more than one subtype, might result in intersubtype recombinants and changes in the
locally prevailing FIV clades [16,17,26,27,30–34,41,42,50].
The laboratory diagnosis of FIV infection primarily relies on the detection of antibodies against
FIV in infected cats, since FIV loads in the peripheral blood are usually very low and antibodies to FIV
are an almost universal feature in FIV-infected cats [51–57]. Furthermore, genetic diversity is known
to lead to challenges in the molecular diagnosis of the infection [31,54,58–60]. The recombination
of viral strains and emerging antigenic variants might also result in antibodies that are no longer
recognized by common diagnostic tests [53,61–64]. For practitioners, diagnostic point-of-care tests
(POCT) that quickly detect antibodies are the method of choice [53,65–69]. Antibodies against the FIV
transmembrane protein (TM) are the most reliable in terms of both their initial appearance post infection
and their duration of detection in the blood [52,53,70–72]. Therefore, many POCT and enzyme-linked
immunoassays (ELISA) used in diagnostic laboratories use FIV-TM as the capture antigen, but capsid
protein has also been added to some tests [56,66,68,73]. The detection of FIV antibodies by Western
blot (WB) is considered the gold standard and is used for the confirmation of FIV diagnosis in cases of
ambiguous POCT and ELISA results [56,65,70,74–77]. In addition, WB is recommended to confirm any
ELISA- and POCT-positive results in countries with a low FIV prevalence, since the positive predictive
value of positive ELISA and POCT results is low under these circumstances [56,76,78].
For many years, samples from cats suspected of FIV infection (ambiguous or positive POCT results)
have been sent to our laboratory for the confirmation of FIV diagnosis using Western blotting [70,74].
Furthermore, we have been receiving samples for primary FIV screening purposes with FIV-TM
ELISA [53]. During routine testing, samples would be sporadically found that were negative for
FIV-TM ELISA and positive for WB. This phenomenon had already been described during the
development of the FIV-TM ELISA in 1995, but this was found for only four of 194 tested samples, and
they were all from cats that lived outside of Switzerland [53].
We hypothesized that the number of FIV infections that are undetectable by FIV-TM ELISA and
POCT has increased over the years due to an increased number of cats with a travel or import history,
which has thus introduced novel FIV isolates into the sample population. Thus, the aim of this study
was to systematically test samples that have been sent to our laboratory over two decades (1998–2019)
using FIV-TM ELISA as well as WB, which is the gold standard for FIV testing. In cases of discrepant
results with sufficient sample volumes, two commercially available POCT (SNAPTM Combo Plus FeLV
Ag/FIV Ab, IDEXX Laboratories, Westbrook, ME, USA; WITNESSR FIV, Zoetis, Delémont, Switzerland)
and RT-PCR assays [58,60,79,80] (FTvet Feline Anaemia I, Fast Track Diagnostics, Esch-sur-Alzette,
Luxembourg) were performed. In addition, an attempt was made to sequence all RT-PCR-positive
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samples. The study included a total of 1194 samples, including 536 samples from FIV-infected cats,
based on WB analysis.
2. Materials and Methods
2.1. Serum Samples
Feline plasma and serum samples submitted to the Clinical Laboratory, Vetsuisse Faculty,
University of Zurich, Switzerland, from the end of 1998 until the beginning of 2019, were available for
this study. The samples had been taken by veterinary practitioners as part of a diagnostic workup and
were sent to the laboratory for routine diagnostic purposes; only leftover samples were used, and no
additional blood volume was collected for the current study. No ethical approval was necessary for
this study in compliance with Swiss regulations [81].
2.2. FIV-TM ELISA
The FIV-TM ELISA was performed as previously described [53], with some modifications. Feline
serum samples were diluted 1:4500 and tested in duplicate. A positive and negative control was run
with each plate. For the positive control, pooled sera from experimentally FIV-infected cats were used
for every run [82]. The negative control consisted of heat-inactivated bovine serum. The plate was
then incubated for one hour at 37 ◦C and washed three times. Horseradish peroxidase-labeled goat
anti-cat immunoglobulin G (H+L) (Jackson Immunoresearch Laboratories, West Grove, PA, USA) was
used as a conjugate and was diluted 1:1000. The absorbance was measured by an ELISA plate reader
(SPECTRAmax PLUS 384, Bucher Biotec AG, Basel, Switzerland) at 405/550 nm. The optical density
(OD) values of the cat serum samples were expressed as percentages of the value obtained from the
positive control sera. Results that were >50% in comparison with the positive control were classified as
positive, whereas those that were <10% were classified as negative and those that were 10–50% were
classified as ambiguous.
2.3. FIV WB
The WB was conducted as previously described using 500 ng of gradient-purified FIV Z2, which
was propagated in feline specified-pathogen free lymphocyte cultures in the presence of recombinant
interleukin-2 [53,70,74]. Feline serum samples were diluted 1:50 and incubated with WB strips overnight
on a rocker platform at room temperature. A peroxidase-labeled goat anti-cat immunoglobulin G
(H+L) conjugate (Jackson Immunoresearch Laboratories) was diluted 1:1000 and incubated for two
hours; after a washing step, the substrate (4-chloronaphtol, HRP Color Development 4CN, Bio-Rad
Laboratories, Hercules, CA, USA) was added. A positive (serum from a FIV-positive cat) and negative
control (buffer only) were run for each blot. The WB was considered positive if two bands with
a molecular weight of 15,000 (p15) and 24,000 (p24) Dalton, respectively, were recognizable on the
blotting strip [74]. If both bands were absent, the sample was judged as WB-negative. Samples that
yielded only one band, either p24 or p15, were judged as inconclusive. WB-positive and negative
results, but not inconclusive results, were included in the statistical analysis.
2.4. FIV Point-of-Care Testing
Depending on the remaining sample volume, ELISA-negative and WB-positive samples were
tested using two different point-of-care tests: WITNESSR FIV (Zoetis, Delémont, Switzerland) and/or
SNAPTM FeLV Ag/FIV Ab Combo Plus (IDEXX Laboratories, Westbrook, ME, USA). The kit materials
and samples were allowed to warm to room temperature before performing the test (SNAPTM) or were
used directly (WITNESSR) according to the manufacturer’s recommendations, and the reading of the
results was performed 10 min after the activation of the test.
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2.5. FIV RT-PCR Analysis
ELISA-false negative (WB-positive) samples that underwent one or both POCT tests and that had
enough remaining volume for additional tests (n = 59) were further analyzed by RT-PCR. Additionally,
a few ELISA false-negative samples with too little volume for combined POCT and RT-PCR analyses
(n = 6) underwent only RT-PCR to increase the chance of viral RNA confirmation in at least one
discordant sample. Moreover, some samples from FIV-infected cats (ELISA- and WB-positive) were
included as controls. Total nucleic acid was extracted from 100 µL of EDTA anticoagulated blood (1/65)
using the MagNAR Pure LCR Total Nucleic Acid Isolation Kit (Roche Diagnostics GmbH, Mannheim,
Germany) or RNA from 140 µL anticoagulated plasma or serum (64/65) with the QIAampR Viral RNA
Kit (QIAGEN GmbH, Hilden, Germany). Notably, prior to nucleic acid extraction, the samples had
undergone an unknown number of freeze–thaw cycles, and some of them had been stored for up to
20 years at −20 ◦C. Negative controls consisting of 100 or 140 µL of phosphate buffered saline were
prepared with each extraction batch to monitor cross-contamination.
Nucleic acid samples were analyzed by real-time RT-PCR that allowed the amplification of various
FIV isolates from clades A and B as described previously [58,60], with the following modifications:
the final reaction volume of 25 µL contained 800 nM of each primer (FIV551f/FIV571r), 160 nM of the
fluorogenic probe (FIV581p), 12.5 µL 2× RT qPCR Mastermix and 0.125 µL of a master mix containing
6.25 U Euroscript reverse transcriptase and 2.5 U RNase inhibitor (One Step RT qPCR MasterMix Plus
Low ROX, Eurogentec Headquarters, Seraing, Belgium). The cycling conditions were as follows: 30
min at 48 ◦C for reverse transcription, followed by an initial denaturation for 10 min at 95 ◦C and
45 amplification cycles at 95 ◦C for 15 s and 60 ◦C for 1 min as previously described by using a 7500
Fast Real-Time PCR System (ThermoFisher Scientific, Zug, CH) [60]. A second real-time RT-PCR was
performed according to a modified version of the method used by Wang et al. [80], which used 900
nM of both the upstream (FIV_gag_upstr: 5′- ATG GGG AAY GGA CAG GGG CGA GA-3′) and
downstream (FIV_gag_downstr: 5′- TCT GGT ATR TCA CCA GGT TCT CGT CCT GTA-3′) primers
and 250 nM fluorogenic probe (FIV_gag_F2ABCEmIM 5′-FAM-TGG CCA TWA ARA (iQ500)GAT GYA
GTA ATG TTG CTG TAG G-BHQ1-3′), 0.625 µL (40 U/µL) RNasinR Plus (Promega, Madison, WI, USA),
12.5 µL 2× RT qPCR Reaction Mix, 0.5 µL SuperscriptTM III RT/PlatinumR Taq mixture and 0.05 µL ROX
(all from the SuperscriptTM III PlatinumTM One-Step qRT-PCR kit, ThermoFisher Scientific, Carlsbad,
CA, USA) in a final volume of 25 µL. The reaction mix underwent reverse transcription at 50 ◦C for 15
min, denaturation and activation for 2 min at 95 ◦C and 45 cycles of 95 ◦C for 15 s and 60 ◦C for 30 s. In
addition, the nucleic acid samples were tested using a commercially available real-time RT-PCR kit
(FTvet Feline Anaemia I, Fast Track Diagnostics, Esch-sur-Alzette, Luxembourg). Finally, a seminested
RT-PCR was performed that amplified a 470 bp-long sequence from the FIV clade A and B gag gene
using primers previously described [79,83] with a concentration of 200 nM of each primer in the first
round and 1 µM of each primer in the second round. The final reaction volume was 25 µL in both
rounds; 12.5 µL 2× Reaction Mix, 1 µL SuperscriptR polymerase (SuperscriptR III One-Step RT-PCR
with PlatinumR Taq Kit, ThermoFisher Scientific) and 0.31 µL (40 U/µL) RNasinR Plus (Promega) were
used in the first round, whereas 2.5 µL 10× buffer, 1.5 µL MgCl2, 1.25 µL (5 U/µL) Taq DNA Polymerase
(Sigma-Aldrich, St. Louis, MO, USA) and 0.5 µL dNTPs (ThermoFisher Scientific, Vilnius, Lithuania)
were used in the second round. Briefly, a reverse transcription step was performed for 30 min at 55 ◦C,
followed by the first round of PCR, which consisted of 2 min at 94 ◦C, 40 cycles of 15 s at 94 ◦C, 1 min at
53 ◦C and 1 min at 73 ◦C, and a final step of 5 min at 68 ◦C. Then, for the second round, 5 µL of the first
round PCR product was used with the following cycling conditions: five minutes at 95 ◦C, followed by
40 cycles of 30 s at 95 ◦C, 30 s at 58 ◦C and 1 min at 72 ◦C and a final elongation step of 10 min at 72
◦C. The PCR products from the second round of PCR were analyzed by agarose gel electrophoresis
(2%). All bands of the expected length were purified (QIAQuickR Gel Extraction Kit, QIAGEN GmbH)
and submitted for sequencing (Microsynth AG, Balgach, Switzerland). The sequences were edited
and assembled using GeneiousR 11.1.5 software (Biomatters, Ltd., Auckland, New Zealand). Using
Viruses 2019, 11, 697 5 of 19
a basic local alignment search tool (NCBI: https://blast.ncbi.nlm.nih.gov/Blast.cgi), we aimed to find
similarities between the isolated sequences and published FIV sequences.
2.6. Diagnostic Sensitivity and Specificity of FIV-TM ELISA
WB has been considered the gold standard to accurately identify FIV positive and negative
samples. The diagnostic sensitivity, specificity and efficiency of FIV-TM ELISA were calculated.
2.7. Statistics
The data were compiled in Microsoft Excel 2016 and analyzed using GraphPad Prism 8 (Version
8.1.0; GraphPad Prism Software, La Jolla, CA, USA). The frequencies were compared using Fisher’s
exact test (pF). The ages of the cats in different groups were compared using the Mann–Whitney U-test
(pMWU). p-values < 0.05 were considered statistically significant.
3. Results
3.1. Sample Characteristics and Results of FIV WB Testing
Of the 1194 cats included in the study, ages were known for 700 cats (59%), and the median age
was 5.0 years (Table 1). The sex of 712 (60%) cats was known: 192/1194 (16%) and 289/1194 (24%) were
intact males or castrated males, respectively; 104/1194 (9%) and 127/1194 (11%) were intact or spayed
females, respectively (Table 1). The samples were obtained from Switzerland (641/1194; 54%), Germany
(475/1194; 40%), France (53/1194; 4%), Austria (5/1194; 0.4%), Finland (9/1194; 0.8%), and Italy (2/1194;
0.2%). For nine samples, the country of origin was unknown.
Table 1. Sample characteristics: Sex, age, and origin of the cats that underwent FIV WB and
ELISA testing.
All Samples
WB-Negative/
Inconclusive
Samples 1
WB-Positive
Samples 1
WB-Positive 1,
ELISA-Positive
Samples
WB-Positive 1
Samples with
Ambiguous
ELISA Results
WB-Positive 1,
ELISA-Negative
Samples
Total 1194 411/247 536 441 25 70
Sex
- m 192 65/36 91 74 2 15
- mc 289 64/53 172 155 3 14
- f 104 44/26 34 24 0 10
- fs 127 67/22 38 31 1 6
- unk 482 171/110 201 157 19 25
Age (y)
- < 6 months 2 46 23/12 11 6 1 4
- 6 months to < 2 y 113 49/25 39 29 0 10
- 2 to < 6 y 210 70/48 92 74 4 14
- 6 to < 10 y 151 44/31 76 63 0 13
- 10 to < 14 y 125 45/25 55 50 0 5
- 14 to < 18 y 47 18/14 15 8 0 7
- 18 to < 23 y 8 6/1 1 1 0 0
- unk 494 156/91 247 210 20 17
Origin
- CH 641 235/145 261 216 7 38
- DE 475 134/88 253 215 11 27
- FR 53 30/9 14 2 7 5
- AT 5 3/2 0 0 0 0
- FI 9 5/3 1 1 0 0
- IT 2 1/0 1 1 0 0
- unk 9 3/0 6 6 0 0
Collection (y)
1998–2003 252 99/28 125 117 3 5
2004–2008 211 44/53 114 83 7 24
2009–2013 276 124/56 96 84 8 4
2014–2019 455 144/110 201 157 7 37
1 FIV-negative and FIV-positive were defined according to the gold standard test, WB; samples producing one band
in WB are “inconclusive”; 2 maternal antibodies are possible in WB-positive cats known to be younger than 6 months
of age; unk = unknown; m = male, mc = castrated male, f = female, fs = spayed female; y = years; CH = Switzerland,
DE = Germany, FR = France, AT = Austria, FI = Finland, IT = Italy.
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3.2. Comparison of WB-Negative and WB-Positive Cats
The results from the FIV WB analyses were used as the gold standard for the determination of
FIV status in cats [53,70,74]. Of the 1194 tested samples, 536 were FIV WB-positive and 411 were FIV
WB-negative, and 247 had inconclusive results because they produced only one band in WB (Table 2).
Table 2. Comparison of FIV WB and FIV ELISA results.
WB-Positive WB-Negative WB-Inconclusive 2 Total
ELISA-Positive
(OD <50% of pc 1) 441 11 36 488
ELISA-Negative
(<10% of pc) 70 375 205 650
Ambiguous Result
(10–50% of pc) 25 25 6 56
Total 536 411 247 1194
1 pc = positive control run with every ELISA; 2 WB-inconclusive samples result in only one band, p24 or p15.
Of the 536 WB-positive cats, the age of 289 was known; the median age of the WB-positive cats was
6.0 years (Table 1). Seventeen cats were 0.5 years old or younger; the FIV-positive results in these cats
could be the result of maternal antibodies. The sex of 335 WB-positive cats was known: the positive
samples originated from 91 (27%) intact males, 172 (51%) neutered males, 34 (10%) intact females, and
38 (11%) spayed females (Table 1). Most of the WB-positive samples came from Switzerland (n = 261)
and Germany (n = 253); only a few samples were sent from other countries (Table 1).
Of the 411 WB-negative cats, the age was known for 255 cats: the median age of the WB-negative
cats was 4.0 years (Table 1). Information about the sex was available for 240 cats: there were 65
intact male (27%), 64 neutered male (27%), 44 intact female (18%), and 67 spayed female cats (28%).
WB-negative samples were sent from Switzerland (n = 235), Germany (n = 134), France (n = 30), Austria
(n = 3), Finland (n = 5), and Italy (n = 1); for three samples, the origin was unknown.
The samples included in this study were not collected randomly but originated mainly from cats
who were clinically suspected of FIV infection; nonetheless, some basic descriptive analyses were
performed. FIV WB-positive cats were significantly more likely to be male, either intact or castrated
(263/335; 79%) than FIV WB-negative cats (129/240; 54%; pF < 0.0001) (Table 1). The median age differed
significantly between WB-positive (median age 6.0 years) and WB-negative cats (median age 4.0 years)
(pMWU = 0.0360). FIV WB-positive samples originated less frequently from Switzerland (261/530; 49%)
than WB-negative samples (235/408; 58%; pF = 0.0122).
3.3. Confirmation of FIV-TM ELISA Results Using FIV WB
Most of the WB-negative samples (375/411; 91%) were FIV-TM ELISA-negative or showed an
ambiguous result according to ELISA (25/411; 6%; Table 2). It is recommended that ambiguous FIV-TM
ELISA results be directly retested by WB. Therefore, they do not pose an imminent problem in terms
of the diagnosis of FIV infection (false positive/false negative) and were not further analyzed in this
study. However, 3% of the WB-negative samples (11/411) were found to be false-positive according to
FIV-TM ELISA.
Of the 536 samples that were FIV WB-positive, 441 (82%) were also TM ELISA-positive, and
25 (5%) revealed an ambiguous result. Remarkably, 70 WB-positive samples (13%) were negative
according to TM ELISA (Table 2).
The diagnostic sensitivity (true positives/all positives) of FIV-TM ELISA was 82% (441/536); the
diagnostic specificity (true negatives/all negatives) was 91% (375/411), and the diagnostic efficiency
(correct tests/all tests) was 86% (816/947).
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3.4. False ELISA-Positive Samples (WB-Negative and FIV-TM ELISA-Positive)
Overall, 11 cats were false-positive according to FIV-TM ELISA (WB-negative but ELISA-positive;
Table 3). For eight samples, a sufficient volume was available to test them also using one or both of the
POCT. Two samples tested negative in both POCT and six were positive in at least one or both of the
POCT performed (Table 3). For three samples, no POCT could be performed. POCT-negative samples
had OD values in the FIV-TM ELISA in the low positive range, according to our definition (positive
>50% of the positive control). POCT-positive samples had, with one exception, OD values >100% of
the positive control in the FIV-TM ELISA.
Table 3. Characteristics of the 11 false ELISA-positive samples (FIV WB-Negative and FIV-TM
ELISA-Positive).
Sample
ID
Age of Cat
(Years) Sex of Cat
Year of
Sample
Collection
Origin of
Sample
(Country)
ELISA (%
of pc)
SNAPTM
POCT
WITNESSR
POCT
1322 15 m 1999 CH 64.0 neg neg
1383 unk m 2000 CH 60.0 nt nt
1436 unk unk 2000 CH 133.7 nt pos
1607 9 m 2004 DE 149.4 pos pos
1758 14 fs 2007 DE 70.7 pos pos
1892 3 mc 2009 CH 75.0 neg neg
1995 6 f 2011 CH 107.9 pos pos
2021 12 fs 2011 CH 51.0 nt nt
2022 10 unk 2011 CH 51.0 nt nt
2023 0.4 m 2011 CH 108.8 pos pos
41673826 7 fs 2017 CH 102.5 nt pos
unk = unknown; m = male, f = female, mc = castrated male, fs = spayed female; nt = not tested since no more
material was available; neg = negative, pos = positive; pc = positive control; CH = Switzerland, DE = Germany.
3.5. False ELISA-Negative Results (WB-Positive and FIV-TM ELISA-Negative)
The characteristics of the cats with false-negative ELISA results (WB-positive but ELISA-negative)
are summarized in Table 1, and the data for each cat are given in Table 4. Such samples originated
more frequently from male cats (29/70; 41%) than from female cats (16/70; 23%). The samples were
sent mainly from Switzerland (38/70; 54%) or Germany (27/70; 39%); five samples were from France
(Table 1). The median age of cats with false-negative ELISA results (5.0 years; Table 1) was lower
than that of cats with FIV WB- and ELISA-positive results (6.0 years; Table 1), and a minimum age of
two months was observed in both groups. The oldest cat with a false-negative ELISA result was 16
years old, while among the WB- and ELISA-positive cats, 18 years was the maximum age. For several
sampling years, there were only one or two false-negative cases per year (<10% of all WB-positive
samples sent in the respective year), while there were four discordant cases each in 2004 and 2006
and fourteen in 2005 (17%/41%/31% of all WB-positive samples in 2004/2005/2006, respectively). The
discordant samples represented 15% of all WB-positive samples in 2014 (n = 3), 29% in 2015 (n = 12),
24% in 2016 (n = 11), and 19% in 2017 (n = 8) (Table 1, Table 4).
Table 4. Characteristics of the 70 false ELISA-negative samples (FIV WB-positive and FIV-TM
ELISA-negative).
Sample
ID
Age of Cat
(Years)
Sex of
Cat
Year of
Sample
Collection
Origin of
Sample
(Country)
SNAPTM
POCT
WITNESSR
POCT
ELISA
(% of pc) RT-PCR
1343 unk unk 1999 CH neg neg 1.5 neg
1359 1 m 1999 CH neg neg 1.7 neg
1537 4 mc 2002 DE neg neg 0.0 neg
1554 8 fs 2003 CH neg neg 3.1 neg
1574 7 mc 2003 CH neg neg 1.3 neg
1599 5 f 2004 DE neg neg 0.0 neg
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Table 4. Cont.
Sample
ID
Age of Cat
(Years)
Sex of
Cat
Year of
Sample
Collection
Origin of
Sample
(Country)
SNAPTM
POCT
WITNESSR
POCT
ELISA
(% of pc) RT-PCR
1621 unk unk 2004 CH nt neg 0.0 neg
1633 3 fs 2004 DE neg neg 3.3 neg
1634 8 f 2004 DE nt nt 1.5 neg
1648 unk unk 2005 CH nt neg 0.0 neg
1656 1 m 2005 DE nt nt 0.0 neg
1666 unk unk 2005 CH neg neg 0.0 neg
1674 0.2 1 m 2005 CH neg neg 0.0 neg
1678 2 mc 2005 DE nt nt 0.0 neg
1679 0.25 1 m 2005 DE nt neg 0.0 nt
1683 0.5 m 2005 DE neg neg 3.0 neg
1686 unk m 2005 DE neg neg 0.0 neg
1690 3 unk 2005 CH neg neg 0.6 neg
1691 13 mc 2005 DE nt nt 0.0 neg
1692 unk unk 2005 CH nt nt 0.0 neg
1698 8 m 2005 DE nt neg 0.0 neg
1699 8 mc 2005 DE neg nt 0.0 nt
1700 5 mc 2005 DE neg neg 0.0 neg
1701 14 fs 2006 DE neg nt 0.0 nt
1703 13 mc 2006 DE nt nt 0.0 neg
1704 2 mc 2006 CH neg neg 0.0 neg
1710 3 mc 2006 DE neg nt 0.0 neg
1781 6 f 2007 DE neg neg 0.0 pos 2
1812 2 f 2008 DE neg neg 2.5 neg
1886 unk unk 2009 FR pos pos 9.0 pos 2
1922 unk unk 2010 DE nt neg 0.0 neg
1925 unk unk 2010 FR nt neg 0.0 neg
00005100 0.25 1 m 2013 CH pos pos4 6.0 nt
00006038 unk unk 2014 DE neg neg 0.0 neg
00007702 unk unk 2014 DE neg neg 0.0 neg
00007792 0.5 m 2014 DE nt neg 1.6 neg
00008569 9 mc 2015 DE neg neg 0.0 neg
00009944 6 mc 2015 CH neg neg 0.0 neg
00009955 unk unk 2015 FR pos nt 8.0 nt
00010012 1 m 2015 CH neg neg 0.0 neg
00010489 0.6 mc 2015 CH nt neg 0.9 neg
00010545 0.31 f 2015 CH neg neg 2.0 neg
41385749 10 unk 2015 CH neg neg 0.0 pos 3
41386411 12 unk 2015 CH neg neg 0.2 neg
41387194 2 unk 2015 CH neg neg 0.4 neg
41387409 10 unk 2015 CH neg neg 0.2 neg
41388050 16 unk 2015 CH neg neg 0.3 neg
41388399 6 unk 2015 CH neg neg 0.1 neg
41392409 16 unk 2016 CH neg neg 1.5 neg
00010770 unk f 2016 DE neg neg 0.0 neg
41397627 8 unk 2016 CH neg neg 0.1 neg
41398102 6 unk 2016 CH neg neg 0.2 neg
41404918 14 m 2016 CH neg neg 2.0 neg
41406670 1 m 2016 CH neg neg 0.0 neg
41406844 0.5 f 2016 CH neg neg 0.2 neg
00011456 3 fs 2016 CH neg neg 1.1 neg
41561426 16 f 2016 CH neg neg 0.3 neg
41577198 14 m 2016 CH neg neg 0.3 neg
00012612 4 fs 2016 CH neg neg 9.9 neg
00013274 unk unk 2017 FR nt neg 0.0 neg
00013276 unk unk 2017 FR nt neg 4.1 neg
00013381 7 mc 2017 CH neg neg 1.0 neg
00014059 0.8 f 2017 DE neg neg 3.0 neg
00014227 unk unk 2017 DE neg neg 1.6 neg
00014598 2 m 2017 CH nt neg 0.0 neg
41663426 16 mc 2017 CH neg neg 0.0 neg
41669714 7 m 2017 CH pos neg 3.6 pos 2
00016295 unk unk 2018 DE pos neg 5.3 neg
00018980 0.7 fs 2019 CH neg neg 5.0 neg
51028174 2 f 2019 CH nt neg 8.0 neg
1 maternal antibody presence possible; 2 FTvet Feline Anaemia I-positive, CT-value = 38–40; 3 seminested RT-PCR:
weakly positive [79,83]; 4 only positive after the regular reading time at 10 min; unk = unknown, m = male, f = female,
mc = castrated male, fs = spayed female; nt = not tested since no more material was available; neg = negative,
pos = positive; pc = positive control; CH = Switzerland, DE = Germany, FR = France.
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3.6. Further FIV Testing of False ELISA-Negative Samples
Of the 70 samples with false-negative ELISA results (WB-positive and TM ELISA-negative),
64 could be tested with at least one of the two POCT, WITNESSR or SNAPTM. Sixty samples had
enough sample volume to perform the first POCT (WITNESSR), and 48 of these also had enough
volume to perform the second POCT (SNAPTM). Four additional samples were only tested in the
SNAPTM test (in total, 52 samples were SNAPTM-tested). In the WITNESSR test, one sample (2%) tested
clearly positive (Table 4). One sample (sample ID 00005100) showed a band only after the regular
reading time at 10 min had passed, and 58/60 (97%) were clearly negative. Of the 52 samples used
in the SNAPTM test, five samples (10%) were positive and 47/52 (90%) were negative (Table 4). Both
samples that tested positive or late positive in the WITNESSR test were also positive in the SNAPTM
test. The SNAPTM test detected two additional samples that were negative in the WITNESSR test and
one that was not tested with the WITNESSR test. While most of the false ELISA-negative samples
had very low ODs according to FIV-TM ELISA (0–3%), one of the samples that was double positive
in the two POCT and one sample that was only tested with the SNAPTM test had ODs of 9.0% and
8.0%, respectively, which were just barely below the cut-off value for ambiguous samples (Table 4).
An additional sample that was negative in both POCT showed a result of 9.9% (sample ID 00012612),
which was just at the cut-off value of 10% for FIV-TM ELISA. The two SNAPTM/WITNESSR double
positive samples and the positive sample that was tested only with the SNAPTM test were sent from
France and Switzerland, and the two samples that were detected solely by the SNAPTM test were from
Germany and Switzerland.
Enough sample volume remained for 65 of the 70 discordant samples for nucleic acid extraction
and to perform FIV RT-PCR. In six of the 65 samples tested using RT-PCR, no POCT was performed
because the remaining material was sufficient only for POCT or RT-PCR. To increase the chance of
RT-PCR confirmation and subsequent sequencing in the discordant samples, it was decided to use
RT-PCRs for these low volume samples. None of the 65 samples tested positive by a previously
described FIV real-time RT-PCR that allowed the amplification of various FIV isolates from clades A
and B [60] or by a modification of a RT-PCR method described by Wang [80]. Three samples tested
weakly positive (CT-values: 38/39/40) according to a commercial real-time RT-PCR kit (FTvet Feline
Anaemia I; Table 4). The seminested RT-PCR revealed a very weak band for one cat that could not be
sequenced. Five ELISA- and WB-positive samples were also analyzed as controls using RT-PCR. The
five samples had high OD values in the TM ELISA (>100%) and were positive in both POCT. All five
samples were positive according to at least two different RT-PCR assays (Table 5). A BLAST search of
the sequences demonstrated high similarities to deposited sequences from subtypes A and B.
Table 5. Characteristics of five ELISA- and WB-positive control samples.
Sample
ID
Age of Cat
(Years)
Sex of
Cat
Year of
Sample
Collection
Origin of
Sample
(Country)
ELISA
(% of pc)
SNAPTM
POCT
WITNESSR
POCT
RT-PCR
1600 2 mc 2004 DE 111.0 pos pos pos 1,2
1622 2 mc 2004 DE 132.8 pos pos pos 1,2
1637 2 mc 2004 CH 182.3 pos pos pos 1,2
00015713 8 mc 2017 CH 179.2 pos pos pos 1,2
00016945 12 fs 2018 CH 265.5 pos pos pos 1,2,3
1 FTvet Feline Anaemia I-positive, CT-value = 30–40; 2 seminested RT-PCR-positive [79,83]; 3 RT-PCR-positive [60],
CT-value = 33; mc = castrated male, fs = spayed female; pos = positive; pc = positive control; CH = Switzerland,
DE = Germany.
3.7. Inconclusive WB Results
We found 247 samples with inconclusive WB results (Table 2). Of these samples, the majority
showed antibodies against p24 (230/247, 93%); only a few had a p15 band (17/247; 7%). Of the
247 samples, 36 were ELISA-positive, of which 30 had OD values ranging from 100% to 440% of that
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of the positive control; 205 tested ELISA-negative and six had an ambiguous result in the FIV-TM
ELISA (Table 2). Animals with inconclusive WB results are recommended to be retested two to three
months later.
4. Discussion
In the present study, we investigated our hypothesis that the number of FIV infections in domestic
cats that are undetectable by FIV-TM ELISA and FIV POCT screening assays has increased over
the years. We have sporadically identified feline plasma and serum samples that were positive
according to a confirmatory FIV WB test but negative according to a FIV-TM ELISA screening assay.
This phenomenon had already been described during the development of the FIV-TM ELISA in 1995,
but it only concerned four of 194 tested samples, and they all originated from cats that had lived
outside of Switzerland [53]. We assumed that the number of discordant samples could potentially
have risen due to an increased number of cats with a travel or import history, which might have
resulted in the introduction of novel FIV isolates in the sample population. For some of the routine
diagnostic cases with discordant results, it was confirmed by veterinarians or the owners that the cats
had been imported. To further investigate our hypothesis, we systematically retested the available
feline plasma and serum samples submitted to our laboratory over the last two decades (1998–2019) for
FIV diagnosis or confirmation using FIV-TM ELISA and WB, which was considered the gold standard
confirmation method.
The results of our study demonstrate an increased percentage of cats in Central Europe that tested
FIV-positive by WB, but FIV infection in these cats was unrecognized by FIV-TM ELISA as well as
some FIV POCT. In the earlier study mentioned above [53], the FIV-TM ELISA used herein had both
a high diagnostic sensitivity and specificity of 98% and 97%, respectively, when using WB as the
gold standard [53]. Only 2% of the 194 FIV WB-positive samples were negative according to the TM
ELISA [53] compared to 70 out of 536 FIV WB-positive samples (13%) collected from August 1998
to February 2019 and analyzed in the current study. These results were found to indicate a reduced
diagnostic sensitivity of FIV-TM ELISA of 82%, compared to 98% in 1995. In an attempt to corroborate
our results regarding the reduced diagnostic sensitivity of FIV-TM ELISA, we also used two POCT
for samples with ample remaining sample volumes. Remarkably, the two POCT did not recognize
many of the discordant samples. This observation has serious diagnostic implications, since FIV-TM
ELISA as well as FIV POCT are used as screening assays for FIV infection; they should have the highest
sensitivity possible in order not to miss any FIV-infected cats during the primary diagnostic screening
step [75].
In the earlier study in 1995, the four samples with discordant results originated from cats in
countries other than Switzerland, and it was hypothesized that FIV-TM ELISA might be specific for
certain variants of FIV [53,62,64]. It was assumed that for the routine testing of cats within Switzerland
and in the absence of a travel or import history of the cat, the sensitivity of FIV-TM ELISA was
sufficient. However, in the current study, more than half of the cats with discordant results (54%) had
either presented to Swiss veterinarians or were represented by samples that had been sent to a Swiss
laboratory before they were sent for confirmation to our laboratory. This does not necessarily imply
that all these cats had lived in Switzerland; especially in regions close to the border, the country of
the veterinarian was not necessarily the country of the origin of the cat. Therefore, a few of these
cats with an FIV infection that was unrecognized by FIV-TM ELISA might also have lived abroad. In
addition, the remaining 46% of cats with discordant results originated mainly from Germany, and
some originated from France. Moreover, based on personal communication with a cat owner, we knew
that at least one of the cats in Switzerland with a discordant FIV test result was originally imported
from Greece. Based on earlier studies, FIV subtype A is the predominant subtype in Switzerland and
Germany, while in southern Europe and Turkey, FIV subtype B is more common [16,20,24,29,32,34–37].
We were unable to further analyze the prevailing FIV subtypes in the cats with discordant results,
since only a few were found to be positive using various RT-PCR assays. Only serum or plasma
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was available, so no provirus PCR, which requires anticoagulated whole blood, could be conducted;
this test usually has a higher sensitivity for FIV infection [84]. Moreover, in the few RT-PCR positive
samples, the viral RNA loads were too low to sequence the virus. Nonetheless, our data indicate that
there is currently an increased number of FIV-infected cats in Switzerland as well as in Germany that
harbor FIV isolates that induce antibodies that are unrecognized by the TM antigen used in FIV-TM
ELISA and the two FIV POCT. Considering the increased travel of cats in Central Europe, particularly
from the East and the South to the North and West of Europe, this might concern more European
countries than just Switzerland and Germany.
TM is the immunodominant epitope in FIV that induces the earliest and strongest antibody
response in cats experimentally infected with FIV [53,62,63,71,72]. Although the evolutionary rate
of FIV is rather slow when compared to other lentiviruses [85] and seems to be dependent on the
virus strain and the infection stage [86], it has been shown that the preferred genetic location for
recombination is in the envelope (env) gene, which also encodes TM [10,25,61,87]. Additionally, low
fidelity in the transcription process and a change in the clade distribution could have contributed to
the increased variability of this protein. The appearance of new viral quasispecies in infected cats has
been reported as being common [50,88]. During virus transmission, these quasispecies infect the new
host and undergo further mutation, hence broadening the genetic diversity [89]. The importance of
the export of domestic cats with virus strains distinct from those locally predominant might result
in a change in virus strain distribution or even the spread of regionally clustered subtypes to new
areas [16,17,26,30,32–34,42]. Taking into account exchanges between zoos, interhost transmission
over wide ranges and behavioral changes caused by human expansion, nondomestic felids are
also a potential source [90–95]. Therefore, not only will intrasubtype recombination occur, but the
development of new subtypes arising from recombination between strains from distinct clusters will
become more likely [16,27,31,41,47].
TM is encoded in the variable env gene and is mainly responsible for the host antibody
response [61–63]. Mutations in the nucleotide sequence can lead to structural changes and result in
antibodies unrecognizable by common diagnostic tests [53,61–64]. In contrast, the capsid protein
p24 and the matrix protein p15 are encoded in the gag region and are considered to be highly
conserved [25,61,96]. Therefore, antibodies to these epitopes, if present, should be more consistently
recognized, and it has been suggested that they be included in serological testing for FIV [53,72].
Both gag proteins are used in the WB analysis as well as in one of the included POCT, the SNAPTM test,
which is an ELISA-based test that also includes TM [53,56,70,73,74,97]. The second POCT included
in this study, the WITNESSR test, is an immune chromatography-based assay that detects antibodies
directed against TM but not against gag proteins, similarly to the FIV-TM ELISA [56,73,98] used
herein. Both POCT showed a low sensitivity in the present study when testing samples from cats with
discordant results. Only five of the tested cats with discordant results (60 for the WITNESSR test and 52
for the SNAPTM test) had a positive POCT result; two of the POCT-positive results could be confirmed
using RT-PCR. A third POCT double positive result was found in a kitten that was 3 months of age. In
a follow-up sample collected at the age of 6 months, the kitten was shown to be FIV-negative by WB;
thus, the initial POCT-positive results at 3 months were most likely due to maternal antibodies and the
RT-PCR result was truly negative, since no viral RNA was present. The fourth SNAPTM POCT-positive
cat was negative according to the WITNESSR POCT test as well as all RT-PCR methods employed.
Because the age of this cat was not known and the SNAPTM signal was weak, the presence of maternal
antibodies was not fully excludable. Two additional FIV WB-positive samples, which were found to be
negative by FIV-TM ELISA and both POCT, were weakly positive according to either Fasttrack RT-PCR
(CT-value of 37.8) or seminested RT-PCR (very weak band). Thus, FIV infection could be confirmed
using a different methodology to detect the virus itself instead of antibodies directed against the virus.
The possibility cannot be completely excluded that these samples were collected during a very early
infection before ample titers of antibodies had developed; the WB method might be somewhat more
sensitive to this kind of early infection. However, we usually do not see both bands, p15 and p24, in
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the early phase of infection [52,53,72], which was the case in these two samples. Overall, 247 samples
in the present study showed inconclusive WB results with only the p24 or p15 band. Some of these
samples might have originated from cats in an early FIV infection. In order to distinguish the latter
from unspecific reactions, animals with inconclusive results according to WB are recommended to be
retested two to three months later for a definite diagnosis.
A limitation of this study is that the samples had been stored at−20 ◦C for up to 20 years. However,
antibodies are not sensitive to long-term storage at −20 ◦C, and repeated freeze–thaw cycles have a
minimal detrimental effect [99]. In contrast, viral RNA is very sensitive to degradation and might
thus have been lost during storage [100]. This might have contributed to the many negative RT-PCR
results in the discordant samples, in addition to the expected low viral loads in many FIV-infected
cats and sequence variation in the FIV genome, which might have led to a lack of recognition by the
oligonucleotides used in the RT-PCR assays. All RT-PCR-positive samples showed very low viral
loads that were too low for sequencing. Because of the long storage of many of the samples, repeated
freeze–thawing cycles, the limited sample volume and uncertainty concerning the sterility of the
samples, we did not consider virus isolation from cell culture. Since not all discordant samples could be
tested with all methods available in this study, it is difficult to compare the results of the different tests.
However, overall, the SNAPTM POCT test seemed to have recognized more of the discordant samples
than the WITNESSR POCT test. Two SNAPTM POCT-positive samples were negative according to the
WITNESSR POCT. It is not quite clear why the SNAPTM POCT, which identifies the gp40, p15, and
p24 antigens, did not detect all WB-positive samples, as antibodies against p15 and p24, two highly
conserved antigens, were obviously present in the samples, since they had been recognized by WB.
One argument for the enhanced sensitivity of WB compared to that of the SNAPTM test could be that
the antigen concentration per strip and the accessibility of the antigen could be higher than that for the
SNAPTM test, in which three antigens share one reaction field. We have no information on the exact
antigens used in the different tests and the conformation and presentation of the antigens. Differences
in the specificities of the antigens in the different tests, the import of new viruses and mutations, and
the recombination of viruses and resulting changes in their antigens and the specificity of induced
antibodies could have contributed to the discordant test results. Moreover, the sensitivity of the
different tests could have played a role. This was obvious in one sample (sample ID 00005100) that was
clearly positive in the SNAPTM POCT but negative in the WITNESSR POCT at the normal reading time
point of 10 min and became weakly positive thereafter. Moreover, one sample (sample ID 00012612)
was just at the cut-off point for a negative result (10%) for FIV-TM ELISA (9.9%). This sample was
negative according to both the SNAPTM and WITNESSR POCT. As the results of all methods except
FIV-TM ELISA are determined by visual inspection, positive samples could be falsely interpreted as
negative if the colorimetric signal was not strong. It has been reported before that the sensitivities of
the POCT used herein differ depending on the respective geographic location and the study cohort
tested from 89 to 100% for the SNAPTM test and 93.8 to 100% for the WITNESSR test [68,73,98,101–103].
The decreased sensitivity of FIV-TM ELISA described over the last twenty years was found based
on a comparison with a study from 1995 [53]. The investigated samples in the current study were
influenced by the number of samples submitted to our laboratory, the awareness of veterinarians
of FIV infection in general and the necessity to test for FIV and to confirm POCT results as well as
the geographic distribution of submitting customers. This has led to a high number of discordant
samples, with up to 14 discordant samples per year in some years and little or no discordant samples
in other years. Therefore, we were unable to determine whether the decrease in sensitivity occurred
gradually over time and whether it poses an increasing problem, but overall it seems to be of significant
relevance. In our study, the number of false-negative samples (n = 70) greatly surpassed the number of
false-positive samples (n = 11); the issue with false-positive results has been generally recognized in
countries with a low FIV prevalence [56,76,78]. The majority of false-positive samples according to
FIV-TM ELISA in our study were also false-positives when tested with the POCT, emphasizing the
need for confirmation using WB to obtain a definitive FIV diagnosis.
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Finally, the discordant samples could also have been falsely WB-positive. We have chosen and
used WB as the gold standard for detecting FIV infection for many years. In countries where no FIV
vaccine is available, which is now the case for the US and has always been the case in Europe, WB is
accepted as the gold standard for FIV diagnosis and for the confirmation of ambiguous and positive
samples [56,65,70,73–76,104]. An alternative method for confirmation of presence or absence of FIV
infection is virus isolation by cell culture. However, this method requires the purification and culture
of fresh peripheral blood mononuclear cells from the cat under investigation ideally with cells from
an uninfected cat; the method is laborious, expensive and time-consuming and is only offered in a
few specialized laboratories [55,56,65,67,105]. No lymphocyte-containing fresh whole blood samples
were available for this study, precluding this option. In agreement with good laboratory practice, we
always run negative and positive controls with each blot to control for false-positive or false-negative
results [106]. Some of the discordant samples in this study could be confirmed to be positive either
using one of the two POCT employed in this study or RT-PCR, even though some of the samples
had been stored for a long time. Finally, there is evidence that WB is more robust for the detection of
antibodies against a variety of felid lentiviruses: WB has been positively used in wild felid species,
such as lions, cheetahs, leopards, or Geoffroy’s cats [3,5,6,9,53,107–110]. For these reasons, we are quite
confident that the WB-positive samples are from cats with true FIV infections.
5. Conclusions
In conclusion, FIV screening solely relying on antibodies directed against a single TM protein
seems to be no longer adequate in geographic areas where cats with imported and new viruses must
be expected. However, a POCT (SNAPTM FIV/FeLV Combo) using additional FIV antigens besides
the immunodominant TM antigen did not recognize all the presumptively FIV-positive cats. Since
ELISA and POCT are used for screening purposes, the inability to recognize an increasing number
of FIV-infected cats poses a serious problem. Currently, it is recommended to confirm any ELISA
and POCT ambiguous or positive results in countries with a low FIV prevalence, since the positive
predictive value of a positive ELISA and POCT result is low under these circumstances [56,76,78].
However, in light of our results, we now additionally recommend that any cat with a high suspicion of
FIV infection and a negative FIV screening test be further investigated using WB for the purposes of
confirmation to exclude false-negative results. Future prospective studies should aim to characterize
in-depth fresh samples from cats with discordant results to identify the underlying viruses to further
improve the laboratory diagnosis of FIV infection.
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